Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

(2010) J Bray et al.   BRITISH JOURNAL OF CANCER

Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review

(2010) Suman Lal et al.   CURRENT DRUG METABOLISM

Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin

(2010) O. S. Bains et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

(2010) Lu Fan et al.   Pharmacogenetics and Genomics

Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci

(2010) E. R. Gamazon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance

(2009) Zachary W. Veitch et al.   Pharmacogenetics and Genomics

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE